Reappraising Genes for Dilated Cardiomyopathy: Stepping Back to Move Forward.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine.Nature reviews. Cardiology · 2025
   Review
2. Genotype is associated with left ventricular reverse remodelling and early events in recent-onset dilated cardiomyopathy.ESC heart failure · 2024
   Article
3. Risk Assessment and Personalized Treatment Options in Inherited Dilated Cardiomyopathies: A Narrative Review.Biomedicines · 2024
   Review
4. The Trouble with Trabeculation: How Genetics Can Help to Unravel a Complex and Controversial Phenotype.Journal of cardiovascular translational research · 2023
   Review

Corrections and comments

• Comment on
  Evidence-Based Assessment of Genes in Dilated Cardiomyopathy.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as